Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Regulation of IL-6 Secretion by Astrocytes via TLR4 in the Fragile X Mouse Model.

Krasovska V, Doering LC.

Front Mol Neurosci. 2018 Aug 3;11:272. doi: 10.3389/fnmol.2018.00272. eCollection 2018.

2.

Altered Developmental Expression of the Astrocyte-Secreted Factors Hevin and SPARC in the Fragile X Mouse Model.

Wallingford J, Scott AL, Rodrigues K, Doering LC.

Front Mol Neurosci. 2017 Aug 29;10:268. doi: 10.3389/fnmol.2017.00268. eCollection 2017.

3.

Abnormal neural precursor cell regulation in the early postnatal Fragile X mouse hippocampus.

Sourial M, Doering LC.

Brain Res. 2017 Jul 1;1666:58-69. doi: 10.1016/j.brainres.2017.04.013. Epub 2017 Apr 23.

PMID:
28442243
4.

Astrocyte-secreted thrombospondin-1 modulates synapse and spine defects in the fragile X mouse model.

Cheng C, Lau SK, Doering LC.

Mol Brain. 2016 Aug 2;9(1):74. doi: 10.1186/s13041-016-0256-9.

5.

Astrocyte-Secreted Factors Selectively Alter Neural Stem and Progenitor Cell Proliferation in the Fragile X Mouse.

Sourial M, Doering LC.

Front Cell Neurosci. 2016 May 18;10:126. doi: 10.3389/fncel.2016.00126. eCollection 2016.

6.

Hippocampal neuronal subtypes develop abnormal dendritic arbors in the presence of Fragile X astrocytes.

Jacobs S, Cheng C, Doering LC.

Neuroscience. 2016 Jun 2;324:202-17. doi: 10.1016/j.neuroscience.2016.03.011. Epub 2016 Mar 8.

PMID:
26968765
7.

Regional brain volumes changes in adult male FMR1-KO mouse on the FVB strain.

Lai JK, Lerch JP, Doering LC, Foster JA, Ellegood J.

Neuroscience. 2016 Mar 24;318:12-21. doi: 10.1016/j.neuroscience.2016.01.021. Epub 2016 Jan 12.

PMID:
26794591
8.

Developmental expression of the neuroligins and neurexins in fragile X mice.

Lai JK, Doering LC, Foster JA.

J Comp Neurol. 2016 Mar 1;524(4):807-28. doi: 10.1002/cne.23868. Epub 2015 Sep 2.

PMID:
26235839
9.

Autism spectrum disorders: emerging mechanisms and mechanism-based treatment.

Wang H, Doering LC.

Front Cell Neurosci. 2015 May 12;9:183. doi: 10.3389/fncel.2015.00183. eCollection 2015. No abstract available.

10.

Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes.

Wang H, Pati S, Pozzo-Miller L, Doering LC.

Front Cell Neurosci. 2015 Feb 26;9:55. doi: 10.3389/fncel.2015.00055. eCollection 2015. Review.

11.

Fluorescent labeling of dendritic spines in cell cultures with the carbocyanine dye "DiI".

Cheng C, Trzcinski O, Doering LC.

Front Neuroanat. 2014 May 9;8:30. doi: 10.3389/fnana.2014.00030. eCollection 2014.

12.

Temporal and spectral differences in the ultrasonic vocalizations of fragile X knock out mice during postnatal development.

Lai JK, Sobala-Drozdowski M, Zhou L, Doering LC, Faure PA, Foster JA.

Behav Brain Res. 2014 Feb 1;259:119-30. doi: 10.1016/j.bbr.2013.10.049. Epub 2013 Nov 7.

PMID:
24211451
13.

Reversing autism by targeting downstream mTOR signaling.

Wang H, Doering LC.

Front Cell Neurosci. 2013 Mar 26;7:28. doi: 10.3389/fncel.2013.00028. eCollection 2013. No abstract available.

14.

Progress toward therapeutic potential for AFQ056 in Fragile X syndrome.

Sourial M, Cheng C, Doering LC.

J Exp Pharmacol. 2013 Jul 16;5:45-54. doi: 10.2147/JEP.S27044. eCollection 2013. Review.

15.

Recent progress in understanding plasticity in neurogenetic disorders.

Wang H, Westmark CJ, Frost E, Doering LC.

Neural Plast. 2012;2012:812472. doi: 10.1155/2012/812472. Epub 2012 Aug 28. No abstract available.

16.

Induced pluripotent stem cells to model and treat neurogenetic disorders.

Wang H, Doering LC.

Neural Plast. 2012;2012:346053. doi: 10.1155/2012/346053. Epub 2012 Jul 19. Review.

17.

Astrocytes and developmental plasticity in fragile X.

Cheng C, Sourial M, Doering LC.

Neural Plast. 2012;2012:197491. doi: 10.1155/2012/197491. Epub 2012 Jul 11. Review.

18.

Probing astrocyte function in fragile X syndrome.

Jacobs S, Cheng C, Doering LC.

Results Probl Cell Differ. 2012;54:15-31. doi: 10.1007/978-3-642-21649-7_2. Review.

PMID:
22009345
19.

Correlative single photon emission computed tomography imaging of [123I]altropane binding in the rat model of Parkinson's.

Gleave JA, Farncombe TH, Saab C, Doering LC.

Nucl Med Biol. 2011 Jul;38(5):741-9. doi: 10.1016/j.nucmedbio.2010.12.006. Epub 2011 Mar 30.

PMID:
21718949
20.

99mTc-based imaging of transplanted neural stem cells and progenitor cells.

Gleave JA, Valliant JF, Doering LC.

J Nucl Med Technol. 2011 Jun;39(2):114-20. doi: 10.2967/jnmt.111.087445. Epub 2011 May 12.

21.

Fragile X astrocytes induce developmental delays in dendrite maturation and synaptic protein expression.

Jacobs S, Nathwani M, Doering LC.

BMC Neurosci. 2010 Oct 18;11:132. doi: 10.1186/1471-2202-11-132.

22.

Astrocytes prevent abnormal neuronal development in the fragile x mouse.

Jacobs S, Doering LC.

J Neurosci. 2010 Mar 24;30(12):4508-14. doi: 10.1523/JNEUROSCI.5027-09.2010.

23.

Isostructural fluorescent and radioactive probes for monitoring neural stem and progenitor cell transplants.

Schaffer P, Gleave JA, Lemon JA, Reid LC, Pacey LK, Farncombe TH, Boreham DR, Zubieta J, Babich JW, Doering LC, Valliant JF.

Nucl Med Biol. 2008 Feb;35(2):159-69. doi: 10.1016/j.nucmedbio.2007.11.001.

PMID:
18312825
24.
25.

Neural stem cells from protein tyrosine phosphatase sigma knockout mice generate an altered neuronal phenotype in culture.

Kirkham DL, Pacey LK, Axford MM, Siu R, Rotin D, Doering LC.

BMC Neurosci. 2006 Jun 19;7:50.

26.

Proliferating brain cells are a target of neurotoxic CSF in systemic autoimmune disease.

Sakic B, Kirkham DL, Ballok DA, Mwanjewe J, Fearon IM, Macri J, Yu G, Sidor MM, Denburg JA, Szechtman H, Lau J, Ball AK, Doering LC.

J Neuroimmunol. 2005 Dec;169(1-2):68-85. Epub 2005 Sep 29.

27.

Transplants of neurosphere cell suspensions from aged mice are functional in the mouse model of Parkinson's.

Meissner KK, Kirkham DL, Doering LC.

Brain Res. 2005 Sep 28;1057(1-2):105-12.

PMID:
16140285
28.
29.

Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers.

Niles LP, Armstrong KJ, Rincón Castro LM, Dao CV, Sharma R, McMillan CR, Doering LC, Kirkham DL.

BMC Neurosci. 2004 Oct 28;5:41.

30.

O2-sensitive K+ channels in immortalised rat chromaffin-cell-derived MAH cells.

Fearon IM, Thompson RJ, Samjoo I, Vollmer C, Doering LC, Nurse CA.

J Physiol. 2002 Dec 15;545(3):807-18.

31.

Protein tyrosine phosphatase sigma-deficient mice show aberrant cytoarchitecture and structural abnormalities in the central nervous system.

Meathrel K, Adamek T, Batt J, Rotin D, Doering LC.

J Neurosci Res. 2002 Oct 1;70(1):24-35.

PMID:
12237861
32.
33.
34.
35.

Glycoproteins E and I facilitate neuron-to-neuron spread of herpes simplex virus.

Dingwell KS, Doering LC, Johnson DC.

J Virol. 1995 Nov;69(11):7087-98.

36.

Ciliary neurotrophic factor promotes the terminal differentiation of v-myc immortalized sympathoadrenal progenitor cells in vivo.

Doering LC, Roder JC, Henderson JT.

Brain Res Dev Brain Res. 1995 Oct 27;89(1):56-66.

PMID:
8575093
37.

Towards gene therapy in the nervous system.

Doering LC.

Clin Neurosci. 1995-1996;3(5):259-61. Review.

PMID:
8914791
38.

Nervous system modification by transplants and gene transfer.

Doering LC.

Bioessays. 1994 Nov;16(11):825-31. Review.

PMID:
7840760
39.

CNTF is superior to NGF as a survival enhancement factor for adrenal medulla cells in vitro.

Tokiwa MA, Gaspar EM, Doering LC.

Neuroreport. 1994 Jan 31;5(5):549-52.

PMID:
8025241
40.

Probing modifications of the neuronal cytoskeleton.

Doering LC.

Mol Neurobiol. 1993 Fall-Winter;7(3-4):265-91. Review.

PMID:
8179841
41.
43.

Second chance for the adrenal medulla transplant.

Doering LC.

Lancet. 1992 Feb 15;339(8790):431. No abstract available.

PMID:
1346692
44.
46.
50.

Supplemental Content

Loading ...
Support Center